An accomplished biotechnology executive with many years of experience in the field, Dr. Lindsay Rosenwald currently acts as a co-founder and partner at an investment partnership. Over the past 20 years, he has worked closely with a wide range of pharmaceutical developers and investors, serving as a trusted partner for businesses looking to grow their operations. In particular, Dr. Lindsay Rosenwald has acquired considerable expertise in the biotechnology financing sector, helping pharmaceutical development companies advance their products and effectively market them.
In recent years, Dr. Lindsay Rosenwald served as a founder and in a leadership capacity for Cougar Biotechnology, which developed a prostate cancer treatment drug known as abiraterone acetate. Johnson & Johnson eventually acquired the company in 2009, a nearly $1 billion transaction that represented a major achievement for a product still in early clinical trials. Dr. Rosenwald has received significant acclaim for his work in the field, earning a number-one ranking on the Genetic Engineering & Biotechnology News’ Molecular Millionaires list for 2002.
Aside from his formal work in the field of biotechnology financing, Dr. Lindsay Rosenwald serves in a leadership role for a number of philanthropic organizations. A member of the Board of Visitors of the Smeal College of business at Penn State University, he also supports a wide range of charitable endeavors through his nonprofit Rosenwald Foundation.
To p
